Repligen Co. (NASDAQ:RGEN) has been assigned a consensus rating of “Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $64.20.

Several research firms have recently weighed in on RGEN. Zacks Investment Research lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. ValuEngine lowered shares of Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 4th. Finally, BidaskClub lowered shares of Repligen from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th.

Shares of NASDAQ:RGEN traded down $0.56 during mid-day trading on Friday, hitting $68.38. The company had a trading volume of 1,226 shares, compared to its average volume of 348,853. The firm has a market capitalization of $3.19 billion, a P/E ratio of 94.45, a P/E/G ratio of 4.09 and a beta of 1.13. The company has a quick ratio of 1.84, a current ratio of 2.18 and a debt-to-equity ratio of 0.03. Repligen has a one year low of $41.88 and a one year high of $71.21.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.02. The company had revenue of $60.63 million during the quarter, compared to analyst estimates of $55.09 million. Repligen had a net margin of 10.11% and a return on equity of 6.35%. Repligen’s revenue for the quarter was up 35.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.17 EPS. On average, analysts anticipate that Repligen will post 0.94 EPS for the current fiscal year.

In related news, CEO Anthony Hunt sold 7,475 shares of Repligen stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $59.01, for a total value of $441,099.75. Following the completion of the sale, the chief executive officer now owns 250,132 shares of the company’s stock, valued at approximately $14,760,289.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 2,240 shares of Repligen stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $58.53, for a total transaction of $131,107.20. Following the transaction, the vice president now directly owns 21,043 shares in the company, valued at $1,231,646.79. The disclosure for this sale can be found here. In the last three months, insiders sold 48,437 shares of company stock valued at $2,855,032. 1.70% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. Vanguard Group Inc. boosted its holdings in Repligen by 28.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,923,135 shares of the biotechnology company’s stock worth $217,577,000 after acquiring an additional 868,093 shares during the last quarter. Lord Abbett & CO. LLC raised its stake in shares of Repligen by 286.3% during the 4th quarter. Lord Abbett & CO. LLC now owns 733,291 shares of the biotechnology company’s stock worth $38,674,000 after purchasing an additional 543,443 shares during the period. Ardevora Asset Management LLP raised its stake in shares of Repligen by 471.7% during the 4th quarter. Ardevora Asset Management LLP now owns 612,077 shares of the biotechnology company’s stock worth $32,281,000 after purchasing an additional 505,020 shares during the period. Voya Investment Management LLC raised its stake in shares of Repligen by 2,173.8% during the 1st quarter. Voya Investment Management LLC now owns 374,219 shares of the biotechnology company’s stock worth $22,109,000 after purchasing an additional 357,761 shares during the period. Finally, Norges Bank bought a new stake in shares of Repligen during the 4th quarter worth $18,352,000. 90.89% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: What is Depreciation?

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.